Suven Pharmaceuticals, CSIR institutes sign MoU for manufacturing anti-Covid drug
The synthetic process know-how for Molnupiravir was sourced from CSIR-NIIST and scale up process was successfully carried out by CSIR-IICT
Hyderabad: Suven Pharmaceuticals Ltd, CSIR-Indian Institute of Chemical Technology, Hyderabad, and CSIR-National Institute of Interdisciplinary Science & Technology, Tiruvananthapuram, have entered into an MoU for the process technology transfer and manufacturing of the anti-Covid drug, Molnupiravir.
The antiviral drug was initially developed for the treatment of influenza and is repurposed to completely suppress the Covid virus transmission within 24 hours according to the study recently published in the Journal Nature Microbiology. The drug could be a game changer in mitigation of SARS-CoV-2 virus, a press release from IICT said.
The synthetic process know-how for Molnupiravir was sourced from CSIR-NIIST and scale up process was successfully carried out by CSIR-IICT. The complete technology know how will be transferred and SPL in turn will manufacture and launch in the market as an effective medication for Covid infected patients.
As per the agreement, CSIR IICT also would provide the process know-how for the manufacture of new anti-Covid drug 2-DG to treat moderately and severely Covid infected patients to reduce their oxygen dependency.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
